Favrille has raised $45 million in a private placement to fund advanced research into its oncology therapy Favld. John P. Longenecker, Ph.D., president and CEO of Favrille, said that the funds should get the company through analysis of its Phase III primary endpoint. Favrille completed Phase III enrollment in January. MPM BioEquities Adviser led the round, which also included Federated Kaufmann Fund, T. Rowe Price Associates, Tang Capital Management, ProMed Management, Forward Ventures, Sanderling Ventures, Alloy Ventures and William Blair Capital Partners.

- read this report in the San Diego Daily Transcript for more information